The Institute for Clinical and Economic Review (ICER) has released a draft report detailing their concerns surrounding Amylyx Pharmaceutical’s new ALS drug Albrioza/AMX0035. The drug has just been conditionally approved in Canada and will likely receive a decision from the US Food and Drug Administration (FDA) this September. In a draft report, ICER points out that the cost-effectiveness of the drug would be thrown off if priced similarly to therapeutics for related neurodegenerative conditions.
According to Ned Pagliarulo, “In assessing cost-effectiveness, ICER used a placeholder price for AMX0035, assuming it might cost as much as the older, infused version of Radicava, which has a list price of $171,000 a year. At that price, however, AMX0035 would surpass ICER’s commonly used thresholds for assessing cost effectiveness.”
To learn more, click here.
(Source: Biopharma Dive, June 14th, 2022)